Objective  To evaluate the clinical efficacy of bifidobacterium triple live bacteria capsules combined with traditional Chinese medicine (TCM) Xilei powder in the treatment of ulcerative colitis (UC).

Methods  A retrospective analysis was conducted of the medical records of patients with UC admitted to the First Affiliated Hospital of Ningbo University between January 2023 and March 2025. According to the treatment plan, patients were divided into a control group (treated with mesalamine) and an observation group (mesalamine+bifidobacterium triple live bacteria capsules+Xilei powder). The two groups were compared in terms of total efficacy rate, relapse rate, symptom relief time, TCM syndrome score, Geboes index, disease activity index (DAI), Baron score, and levels of interleukin (IL)- 6, IL-8, and tumor necrosis factor-α (TNF-α).

Results  A total of 100 patients were enrolled, with 50 in each group. The observation group had a significantly higher total effective rate than the control group (86.00% vs. 70.00%, P<0.05), and a significantly lower recurrence rate than the control group (3-month recurrence 14.00% vs. 32.00%, P<0.05; 12-month recurrence 22.00% vs. 44.00%, P<0.05). The duration of symptom remission was significantly shorter in the observation group than in the control group (P<0.05). The improvement in TCM syndrome score, Geboes index, DAI, and Baron score in the observation group was significantly greater than that in the control group (P<0.05). Levels of inflammatory cytokines (IL-6, IL-8, and TNF-α) in the observation group were significantly lower than those in the control group (P<0.05).

Conclusion  The combination of bifidobacterium triple live bacteria capsules and the TCM Xilei powder has a significant effect in treating UC, shortening the time of symptom relief, reducing the relapse rate, and has a strong anti-inflammatory effect.

1.黄水兰, 张磊昌, 高强强, 等. 中医药防治溃疡性结肠炎机制研究进展[J]. 辽宁中医杂志, 2024, 51(7): 206-212. [Huang SL, Zhang LC, Gao QQ, et al. Research progress on mechanism of traditional Chinese medicine in prevention and treatment of ulcerative colitis[J]. Liaoning Journal of Traditional Chinese Medicine, 2024, 51(7): 206-212.] DOI: 10.13192/j.issn.1000-1719.2024.07.053.

2.崔盈. 检测粪便肝素酶mRNA以评估溃疡性结肠炎活动度并预测其癌变风险[C]//2020年浙江省医学会核医学与放射医学防护分会学术大会论文汇编. 2020: 53-54. DOI: 10.26914/c.cnkihy.2020.071274.

3.逄曜玮, 曹彬, 张炜, 等. 美沙拉嗪治疗轻中度溃疡性结肠炎患者的肠黏膜愈合率分析[J]. 中国医院药学杂志, 2022, 42(8): 844-846. [Pang YW, Cao B, Zhang W, et al. Analysis of intestinal mucosal healing rate in patients with mild to moderate ulcerative colitis treated with me-salazine[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(8): 844-846.] DOI: 10.13286/j.1001-5213.2022.08.15.

4.陶柱萍, 龙宇, 李灿委, 等. 肠道菌群在中草药抗溃疡性结肠炎中的作用[J]. 药学学报, 2021, 56(2): 391-402. [Tao  ZP, Long Y, Li CW, et al. Role of gut microbiota in the treatment of ulcerative colitis with traditional Chinese medicine[J]. Acta Pharmaceutica Sinica, 2021, 56(2): 391-402.] DOI: 10.16438/j.0513-4870.2020-1802.

5.刘力, 张欢. 肠道菌群失调与溃疡性结肠炎[J]. 现代中医药, 2010, 30(2): 45-47. [Liu L, Zhang H. Intestinal flora imbalance and ulcerative colitis[J]. Modern Traditional Chinese Medicine, 2010, 30(2): 45-47.] DOI: 10.13424/j.cnki.mtcm.2010.02.028.

6.廖煜, 杨天文. 双歧杆菌三联活菌联合美沙拉嗪治疗中国炎症性肠病患者疗效及安全性的Meta分析[J]. 山西医科大学学报, 2018, 49(2): 140-147. [Liao Y, Yang TW. Efficacy and safety of bifidobacterium triple viable bacteria combined with mesalmine for Chinese patients with inflammatory bowel disease:a Meta-analysis[J]. Journal of Shanxi Medical University, 2018, 49(2): 140-147.] DOI: 10.13753/j.issn.1007-6611.2018.02.009.

7.郑志敏, 吕冠华, 范颖. 中医药调节肠道菌群治疗溃疡性结肠炎研究进展[J]. 中医临床研究, 2025, 17(13): 134-139. [Zheng  ZM, Lyu GH, Fan Y. A review on traditional Chinese medicine on ulcerative colitis by regulating gut microbiota[J]. Clinical Journal of Chinese Medicine, 2025, 17(13): 134-139.] DOI: 10.3969/j.issn.1674-7860.2025.13.024.

8.那坤, 武亮, 赵冬琰, 等. 谷参肠安胶囊联合锡类散灌肠治疗溃疡性结肠炎的临床观察[J]. 中国中医基础医学杂志, 2016, 22(11): 1501-1503. [Na K, Wu L, Zhao DY, et al. Clinical observation of the treatment of ulcerative colitis patients by GuShenChangAn capsule combined with Xileisan[J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 2016, 22(11): 1501-1503.] DOI: 10.19945/j.cnki.issn.1006-3250.2016.11.028.

9.黄羚, 刘铁钢, 白辰, 等. 经典名方锡类散小考[J]. 中国中药杂志, 2020, 45(17): 4262-4266. [Huang L, Liu TG, Bai C, et al. Textual research on Xilei powder[J]. Chinese Journal of Traditional Chinese Medicine, 2020, 45(17): 4262-4266.] DOI: 10.19540/j.cnki.cjcmm.20191227.501.

10.张玉洁. 溃疡性结肠炎的中西医治疗进展[J]. 山东医学高等专科学校学报, 2025, 47(2): 19-21. [Zhang YJ. Progress in the treatment of ulcerative colitis with traditional Chinese and western medicine[J]. Journal of Shandong Medical Vocational College, 2025, 47(2): 19-21.] DOI: 10.3969/j.issn.1674-0947.2025.02.007.

11.吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见（2018年·北京）[J]. 中国实用内科杂志, 2018, 38(9): 796-813. [Wu KC, Liang J, Ran ZH, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9): 796-813.] DOI: 10.19538/j.nk2018090106.

12.钟子劭, 徐包慧, 陆红, 等. 世界胃肠病学组织全球指南: 幽门螺杆菌[J]. 胃肠病学, 2021, 26(9): 540-553. [Zhong  ZS, Xu BH, Lu H, et al. World gastroenterology organisation global guidelines:helicobacter pylori[J]. Chinese Journal of Gastroenterology, 2021, 26(9): 540-553.] DOI: 10.3969/j.issn.1008-7125.2021.09.005.

13.张娇, 顾树江, 邢凯, 等. 结肠水疗仪中药灌肠联合美沙拉嗪治疗活动期溃疡性结肠炎的疗效与预后观察[J]. 北京中医药, 2025, 44(4): 430-434. [Zhang J, Gu SJ, Xing K, et al. Efficacy and prognosis observation of Chinese medicine enema via colon hydrotherapy device combined with mesalazine in treatment of active ulcerative colitis[J]. Beijing Journal of Traditional Chinese Medicine, 2025, 44(4): 430-434.] DOI: 10.16025/j.1674-1307.2025.04.008.

14.梁茂新, 高天舒. 《中药新药临床研究指导原则》脏腑诸证考察与分析[J]. 中国中医基础医学杂志, 2008, 14(5): 330-331, 342. [Liang MX, Gao TS. Investigation and analysis of syndromes of internal organs in guideline for clinical trials of new patent chinese medicines[J]. Chinese Journal of Basic Medicine in Traditional Chinese Medicine, 2008, 14(5): 330-331, 342.] DOI: 10.3969/j.issn.1006-3250.2008.05.005.

15.任聪, 孟凡艳, 弓彦, 等. 基于免疫、自噬及肠道菌群探究溃结安康汤治疗溃疡性结肠炎作用机制[J]. 中国中医药信息杂志, 2025, 32(3): 119-128. [Ren C, Meng FY, Gong Y, et al. Exploration on the mechanism of Kuijie Ankang decoction in treating ulcerative colitis based on immune, autophagy and intestinal flora[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2025, 32(3): 119-128.] DOI: 10.19879/j.cnki.1005-5304.202404117.

16.宋桃燕, 李永烽. 美沙拉嗪联合双歧三联活菌胶囊治疗溃疡性结肠炎患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(12): 1610-1613. [Song TY, Li YF. Clinical trial of mesalazine combined with bifidotrichoderma capsule in the treatment of patients with ulcerative colitis[J]. Chinese Journal of Clinical Pharmacology, 2020, 36(12): 1610-1613.] DOI: 10.13699/j.cnki.1001-6821.2020.12.003.

17.刘俊杰, 高剑, 黎淑玲. 云南白药保留灌肠联合美沙拉嗪肠溶片+双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床效果观察[J]. 结直肠肛门外科, 2022, 28(2): 138-142. [Liu JJ, Gao J, Li SL. Effects of Yunnan Baiyao retention enema combined with mesalazine enteric-coated tablets and bifidobacterium triple viable capsules for treating ulcerative colitis[J]. Journal of Colorectal & Anal Surgery, 2022, 28(2): 138-142.] DOI: 10.19668/j.cnki.issn1674-0491.2022.02.008.

18.Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives[J]. World J Gastroenterol, 2023, 29(14): 2078-2100. DOI: 10.3748/wjg.v29.i35.5178.

19.Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis[J]. Lancet, 2023, 402(10401): 571-584. DOI: 10.1016/S0140-6736(23)00966-2.

20.Qiu P, Ishimoto T, Fu L, Zet al. The gut microbiota in inflammatory bowel disease[J]. Front Cell Infect Microbiol, 2022, 12: 733992. DOI: 10.3389/fcimb.2022.733992.